Hostname: page-component-5d84bcc8dc-pxjkr Total loading time: 0 Render date: 2026-09-16T08:18:59.923Z Has data issue: false hasContentIssue false

Paragonimus and paragonimiasis in West and Central Africa: unresolved questions

Published online by Cambridge University Press:  13 September 2018

Neil Cumberlidge
Affiliation:
Department of Biology, Northern Michigan University, 1401 Presque Isle Avenue, Marquette, Michigan 49855, USA
David Rollinson
Affiliation:
Department of Life Sciences, Natural History Museum, Cromwell Road, London SW7 5BD, UK
Jozef Vercruysse
Affiliation:
Faculty of Veterinary Medicine, Department of Virology, Parasitology, Immunology, Salisburylaan 133, B-9820 Merelbeke, Belgium
Louis-Albert Tchuem Tchuenté
Affiliation:
Centre for Schistosomiasis and Parasitology, University of Yaoundé I, Yaoundé,Cameroon
Bonnie Webster
Affiliation:
Department of Life Sciences, Natural History Museum, Cromwell Road, London SW7 5BD, UK
Paul F. Clark*
Affiliation:
Department of Life Sciences, Natural History Museum, Cromwell Road, London SW7 5BD, UK
*
Author for correspondence: Paul F. Clark, E-mail: p.clark@nhm.ac.uk

Abstract

Paragonimiasis, human lung fluke disease, is a foodborne anthropozoonosis caused by the trematodes assigned to Paragonimus and is regarded by the World Health Organization as a Neglected Tropical Disease (NTD). The life cycle of this medically important parasite centres on a complex freshwater biological community that includes two intermediate hosts: a mollusc and a decapod, usually a brachyuran. Although there is a perception that the biology, symptoms, diagnosis and treatment of Paragonimus is well understood, in reality, this is not the case, especially in Africa. Much remains unknown concerning the life-cycle of the parasite, its transmission, the current epidemiology of the disease, diagnosis and the effectiveness of treatment. Furthermore, cases of paragonimiasis may be misdiagnosed as resistant tuberculosis (TB) because of the similar pulmonary symptoms and no remission after anti TB therapy. The endemic foci of human paragonimiasis in Africa have been reported mainly in the forest zones of Upper Guinea (Liberia, Guinea and Ivory Coast) and Lower Guinea (Nigeria, Cameroon, Equatorial Guinea and Gabon). Despite the perceived medical importance of paragonimiasis, relatively little attention has been paid to this NTD since its discovery in Africa in the 1960s. This review focuses on the current understanding of the life cycle and transmission of Paragonimus in Africa, discusses its diagnosis and public health importance and highlights many outstanding gaps in the knowledge that still exist for this NTD.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable